Controlled randomized crossover of essential oils for quality of life in children with autism spectrum disorder (ASD): A pilot and feasibility study / Xueliang PAN ; Taylor WONG ; Craig WILLIAMS ; Cheryl JAMES ; L. Eugene ARNOLD in Research in Autism, 125 (July 2025)  

Public ISBD [article]  inResearch in Autism > 125 (July 2025) . - p.202603 Titre : Controlled randomized crossover of essential oils for quality of life in children with autism spectrum disorder (ASD): A pilot and feasibility study Type de document : Texte imprimé et/ou numérique Auteurs : Xueliang PAN, Auteur ; Taylor WONG, Auteur ; Craig WILLIAMS, Auteur ; Cheryl JAMES, Auteur ; L. Eugene ARNOLD, Auteur Article en page(s) : p.202603 Langues : Anglais (eng) Mots-clés : Essential oils  Autism spectrum disorder  Feasibility study  Quality of life  Sleep  Anxiety  Proinflammatory cytokines Index. décimale : PER Périodiques Résumé : Introduction Essential oils have been touted to benefit children with autism spectrum disorder (ASD) in a multitude of ways. However, the lack of empirical evidence makes it difficult to accept this claim. We tested the feasibility of conducting a large randomized clinical crossover trial of an essential oils blend in children with ASD and evaluated its safety and efficacy for improving quality of life. Methods Children ages 3-9 with ASD were randomized to a crossover study of Reconnect?, an essential oils blend, versus a control. Outcomes were the Pediatric Quality of Life Inventory, Parent-Rated Anxiety Scale for ASD, Children?s Sleep Habits Questionnaire, and laboratory safety tests. Inflammatory cytokines and other labs were explored. Mixed-effects analyses were applied. Results Twenty-six participants evaluated as intent-to-treat population. Seventeen completed both conditions (61 %). Outcomes improved, but between-treatment differences in the crossover were nonsignificant (p = .33-.16). At first treatment endpoint, anxiety decreased significantly more with active than control (p = .015, d=1.01). Adverse events and hematological/hepatic/renal tests revealed no significant differences. C-reactive protein and interleukin-6 (IL-6) revealed no inflammation. Conclusion Recruitment was feasible, adherence was high, first-condition retention was high (92.7 %). Retention in second condition was low (65.4 %). A large crossover is not feasible. Anxiety results suggest further study in a randomized controlled trial with a parallel-groups design. Reconnect? appears safe. En ligne : https://doi.org/10.1016/j.reia.2025.202603 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=559 [article] Controlled randomized crossover of essential oils for quality of life in children with autism spectrum disorder (ASD): A pilot and feasibility study [Texte imprimé et/ou numérique] / Xueliang PAN, Auteur ; Taylor WONG, Auteur ; Craig WILLIAMS, Auteur ; Cheryl JAMES, Auteur ; L. Eugene ARNOLD, Auteur . - p.202603. Langues : Anglais (eng) in Research in Autism > 125 (July 2025) . - p.202603 Mots-clés : Essential oils  Autism spectrum disorder  Feasibility study  Quality of life  Sleep  Anxiety  Proinflammatory cytokines Index. décimale : PER Périodiques Résumé : Introduction Essential oils have been touted to benefit children with autism spectrum disorder (ASD) in a multitude of ways. However, the lack of empirical evidence makes it difficult to accept this claim. We tested the feasibility of conducting a large randomized clinical crossover trial of an essential oils blend in children with ASD and evaluated its safety and efficacy for improving quality of life. Methods Children ages 3-9 with ASD were randomized to a crossover study of Reconnect?, an essential oils blend, versus a control. Outcomes were the Pediatric Quality of Life Inventory, Parent-Rated Anxiety Scale for ASD, Children?s Sleep Habits Questionnaire, and laboratory safety tests. Inflammatory cytokines and other labs were explored. Mixed-effects analyses were applied. Results Twenty-six participants evaluated as intent-to-treat population. Seventeen completed both conditions (61 %). Outcomes improved, but between-treatment differences in the crossover were nonsignificant (p = .33-.16). At first treatment endpoint, anxiety decreased significantly more with active than control (p = .015, d=1.01). Adverse events and hematological/hepatic/renal tests revealed no significant differences. C-reactive protein and interleukin-6 (IL-6) revealed no inflammation. Conclusion Recruitment was feasible, adherence was high, first-condition retention was high (92.7 %). Retention in second condition was low (65.4 %). A large crossover is not feasible. Anxiety results suggest further study in a randomized controlled trial with a parallel-groups design. Reconnect? appears safe. En ligne : https://doi.org/10.1016/j.reia.2025.202603 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=559

---

1 (1 - 1 / 1)